LRP-1 Promotes Cancer Cell Invasion by Supporting ERK and Inhibiting JNK Signaling Pathways by Langlois, Benoit et al.
LRP-1 Promotes Cancer Cell Invasion by Supporting ERK
and Inhibiting JNK Signaling Pathways
Benoit Langlois
1, Gwenn Perrot
1, Christophe Schneider
1, Patrick Henriet
2, Herve ´ Emonard
1, Laurent
Martiny
1, Ste ´phane Dedieu
1*
1Universite ´ de Reims Champagne-Ardenne, CNRS UMR 6237 MEDyC, Laboratoire SiRMa, Campus Moulin de la Housse, Reims, France, 2Cell Biology Unit, de Duve
Institute and Universite ´ Catholique de Louvain, Brussels, Belgium
Abstract
Background: The low-density lipoprotein receptor-related protein-1 (LRP-1) is an endocytic receptor mediating the
clearance of various extracellular molecules involved in the dissemination of cancer cells. LRP-1 thus appeared as an
attractive receptor for targeting the invasive behavior of malignant cells. However, recent results suggest that LRP-1 may
facilitate the development and growth of cancer metastases in vivo, but the precise contribution of the receptor during
cancer progression remains to be elucidated. The lack of mechanistic insights into the intracellular signaling networks
downstream of LRP-1 has prevented the understanding of its contribution towards cancer.
Methodology/Principal Findings: Through a short-hairpin RNA-mediated silencing approach, we identified LRP-1 as a main
regulator of ERK and JNK signaling in a tumor cell context. Co-immunoprecipitation experiments revealed that LRP-1
constitutes an intracellular docking site for MAPK containing complexes. By using pharmacological agents, constitutively
active and dominant-negative kinases, we demonstrated that LRP-1 maintains malignant cells in an adhesive state that is
favorable for invasion by activating ERK and inhibiting JNK. We further demonstrated that the LRP-1-dependent regulation
of MAPK signaling organizes the cytoskeletal architecture and mediates adhesive complex turnover in cancer cells.
Moreover, we found that LRP-1 is tethered to the actin network and to focal adhesion sites and controls ERK and JNK
targeting to talin-rich structures.
Conclusions: We identified ERK and JNK as the main molecular relays by which LRP-1 regulates focal adhesion disassembly
of malignant cells to support invasion.
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Introduction
The low-density lipoprotein (LDL) receptor-related protein-1
(LRP-1) is a ubiquitously expressed endocytic receptor belonging
to the LDL-receptor family [1]. First described as a cargo receptor
mediating the uptake and lysosomal degradation of a2-macro-
globulin [2], LRP-1 was then found to be involved in the
internalization of over 30 functionally and structurally unrelated
extracellular ligands. These include proteases, protease-inhibitor
complexes, macromolecular proteins and growth factors. Initially
synthesized as a 600 kDa precursor, LRP-1 is further processed in
the trans-Golgi by a furin-convertase for expression at the cell
surface in the mature two-chain form composed of a 515 kDa
extracellular subunit (a-chain), noncovalently linked to a 85 kDa
b-chain containing the transmembrane domain and cytoplasmic
tail. The LRP-1 a-chain harbors four ligand-binding clusters
involved in the specific recognition of extracellular ligands and the
assembly of multiprotein complexes at the cell surface. The
intracellular domain of the LRP-1 b-chain could recruit molecules
involved in the endocytic machinery and cytoplasmic modulators
of signaling pathways [3].
The diversity of its ligands maye x p l a i nw h yL R P - 1h a sb e e n
identified as a critical factor in diverse pathological contexts
including atherosclerosis and neurodegenerative disorders as the
most frequently described [4,5]. A growing number of evidence
strengthened the putative role of LRP-1 in crucial events during
cancer progression [6]. LRP-1 was indeed reported to mediate
the clearance of various matrix metalloproteinases such as
MMP-2, MMP-9 and MMP-13 [7,8,9] and to regulate the
plasmin activation cascade through endocytosis of tissue-type
(tPA) or urokinase-type (uPA) plasminogen activators [10,11].
Considering its well-known function in the control of matrix
proteolysis [12], LRP-1 was initially proposed as a novel tumor
suppressor. The weak expression level of LRP-1 observed in
high grade human cancer cells and tissues seemed to support
such a hypothesis [13,14]. However, the overall function of
LRP-1 in carcinogenesis appears to be much more complex
than first thought. Recent studies have reported a positive
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11584contribution of LRP-1 to migration and invasion events of
various cell types [10,15,16], including malignant tumor cells
[17,18,19,20]. LRP-1 expression was also reported to be
hypoxia-responsive and to support the metastatic dissemination
of mouse tumor xenografts [21]. Furthermore, LRP-1 was
shown to sustain the mitogenic and/or promigratory effects of
several soluble factors present in the peritumoral environment,
thus supporting a pro-tumorigenesis role of the receptor
[15,22,23]. We recently demonstrated that LRP-1 contributes
to carcinoma cell invasion by subtly controlling adhesive
complex turnover [17]. It therefore appears that the mecha-
nisms by which LRP-1 controls tumor progression are not solely
related to its endocytic function.
Beyond endocytosis, LRP-1 was distinguished by its ability to
trigger intracellular signaling pathways regulating cell prolifera-
tion, differentiation, migration or survival [15,24,25,26]. Its short
intracytoplasmic domain (ICD) contains two NPxY motifs for
phosphorylation by tyrosine kinases which are then able to bind
phosphotyrosine-binding domain (PTB)-containing proteins. Yeast
two-hybrid assays and proteomics analysis revealed that Shc (Src
homology 2 domain containing protein), Fe65, Dab1 (disabled 1),
PI3K (phosphatidyl-inositol 3-kinase) or a PIP-4,5-kinase (phos-
Figure 1. The shRNA-mediated silencing of LRP-1 inhibits ERK and triggers the activation of JNK signaling pathways. (A) Total RNAs
were purified from FTC133 control clonal cell line (shCTRL) or clonal cells that stably overexpress shRNAs for LRP-1 (shLRP-1). The transcriptional level
of LRP-1 was assessed by RT-PCR. b-actin primers were used as a normalization control. (B) Whole-cell extracts from each cell line were subjected to
immunoblot analysis with anti-LRP-1 b-chain antibody (5A6). b-actin antibody was used for normalization. (C) shCTRL and shLRP-1 clonal cells were
cultivated for 24 hours on gelatin-coated surfaces in 10% FBS-containing media. Whole-cell extracts were immunoblotted by using phospho-ERK,
phospho-JNK, phospho-Akt and phospho-p38 antibodies. Antibodies to ERK, JNK, p38 and b-actin were used to ensure equal loading and for
normalization. The gel and immunoblots presented are representative of at least three seperate experiments. Numbers under the gel and
immunolots indicate the fold inductions by comparaison with shCTRL cells.
doi:10.1371/journal.pone.0011584.g001
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LRP-1-ICD [27,28]. Thus, in response to extracellular stimuli,
LRP-1 can recruit intracellular scaffold proteins to trigger
downstream signaling. LRP-1 has been identified as a molecular
signaling partner for platelet-derived growth factor receptor
(PDGFR), leading to migratory and proliferative signaling and
development of atherosclerotic lesions [4,29]. More recently, the
promigratory effect of the plasminogen activator inhibitor PAI-1
appeared to require LRP-1-dependent activation of the JAK (janus
kinase)/STAT (signal transducer and activator of transcription)
signaling pathway [30]. Furthermore, Ma and colleagues reported
that LRP-1 might regulate murine embryonic fibroblasts migra-
tion by suppressing the Rac1 and extracellular signal-regulated
kinase (ERK) pathways [31].
In the cancer field, there is a notable lack of knowledge about
intracellular signaling downstream of LRP-1 and understanding of
its possible contribution to cancer progression. In the present
study, we characterized the molecular signaling relays involved in
the LRP-1-mediated stimulation of cancer cell invasion and
identified the LRP-1 b-chain as a main docking site for focal
adhesion (FA) components and mitogen-activated protein kinase
(MAPK)-containing complexes.
Results
Identification of LRP-1 as a regulator of MAPK signaling
pathways in tumor cell context
T oa s s e s st h er o l eo fL R P - 1i nt h er e g u l a t i o no fi n t r a c e l l u l a r
signal transduction, we used a previously validated method to
generate shLRP-1 clonal cells that stably overexpress a specific
hairpin sequence directed against LRP-1 [17]. As shown in
Fig. 1, we observed a ,90% down-regulation of endogenous
LRP-1 expression in shLRP-1 cells compared with shCTRL
cells, at both mRNA (Fig. 1A) and protein levels (Fig. 1B). We
therefore analyzed the effects of LRP1 silencing on the
activation of several potential LRP-1-regulated signaling
pathways. The activation states of two major MAPK pathways,
i.e., ERK-1/2 and SAPK/JNK (stress-activated protein kinase/
c-jun N-terminal kinase), were first examined (Fig. 1C). We
found that the level of phosphorylated ERK-1/2 was selectively
d e c r e a s e di nL R P 1 - s i l e n c e dc e l l sa n da ni n c r e a s ei nJ N K - 1 / 2 / 3
phosphorylation was detected upon LRP-1 silencing. However,
the phosphorylation levels of Akt and p38 MAPK did not
change significantly in LRP-1-deficient carcinomas. These
results demonstrate that LRP-1 may act as an intracellular
signaling modulator, activating ERK and inhibiting JNK
signaling pathways.
LRP-1 mediates the serum-induced activation of ERK-1/2
and constitutive inhibition of JNK-1/2/3
The LRP-1-mediated regulation of intracellular signaling can
either depend on the binding of extracellular ligands or on the
recruitment of intracellular scaffolds. We assessed LRP-1-mediat-
ed regulation of both ERK (Fig. 2A to 2D) and JNK pathways
(Fig. 2E to 2H) in response to serum stimulation and gelatin
coating. The LRP-1-mediated activation of ERK-1/2 phosphor-
ylation was observed only in the presence of serum (Fig. 2A and 2B
vs 2C and 2D). In contrast, the activation of JNK-1/2/3 in LRP-
1-silenced cells was not conditioned by the presence of serum
(Fig. 2E to 2H). In both cases, the regulation of MAPK by LRP-1
was unaffected by gelatin coating (Fig. 2A, 2C, 2E and 2G). The
LRP-1 receptor therefore triggers the extracellular-ligand-depen-
dent activation of ERK-1/2 and acts as a constitutive inhibitor of
the JNK pathway.
Figure 2. LRP-1 silencing inhibits the serum-mediated activation of ERK and leads to JNK hyperactivation. shCTRL and shLRP-1 cells
were plated on plastic or gelatin-coated dishes for 24 hours in the absence or presence of FBS. Whole-cell extracts were subjected to Western-blot
analysis to study the activation of ERK (A–D) and JNK (E–H) in the absence or presence of FBS. The respective activation rates of ERK (B, D) and JNK
(F, H) were determined as intensity ratios of phospho-protein to corresponding pan-protein and expressed in relative units +/2 SD, with a value of 1
ascribed to shCTRL cells. NS, not significant; *, P,0.05.
doi:10.1371/journal.pone.0011584.g002
Figure3. ERK, JNK andSrcare co-immunoprecipitated withLRP-
1 in tumor cells. Immunoprecipitations of LRP-1-containing complexes
(IP: LRP-1-a) were performed by using anti-LRP-1 a-chain (8G1)
antibodies and the immunocomplexes were immunoblotted (IB) by
using 8G1, anti-LRP-1 b-chain (5A6), anti-ERK-1/2, anti-phospho-ERK-1/2,
anti-JNK-1/2/3, anti-phospho-JNK-1/2/3 and anti-Src antibodies. Nonspe-
cific IgGs were used as a negative control of immunoprecipitation.
doi:10.1371/journal.pone.0011584.g003
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containing complexes
The LRP-1 C-terminal end may interact with scaffold molecules
involved in signal transduction [28]. Coimmunoprecipitation
experiments were performed to test whether the intracellular
domain of LRP-1 is able to recruit targets involved in the
regulation of ERK and JNK signaling pathways in a tumor cell
context. As shown in Fig. 3, we were able to successfully
immunoprecipitate LRP-1 b-chain with an antibody raised against
the extracellular LRP-1 a-chain. Both ERK and JNK kinases were
co-immunoprecipitated with LRP-1 b-chain. We also examined
the phosphorylation state of these kinases. Phosphorylated forms of
ERK-1/2 were found associated with LRP-1, where phosphory-
lated JNK were not. Src, a kinase well-known to be activated
downstream of mitogen and matrix receptors, was also detected in
LRP-1 b-chain containing complexes.
LRP-1-dependent ERK activation contributes to
carcinoma cell invasion
We recently described a key role for LRP-1 in tumor progression
[17]. Indeed, as shown in Fig. 4A, LRP-1-deficient cells exhibited a
two-fold decreased invasive capacity, as compared to control clonal
cells. We therefore investigated whether the LRP-1-dependent
activation of ERK could contribute to carcinoma cell invasion.
First, control cells were treated with U0126, a selective inhibitor of
MEK-1/2 (MAPK ERK kinase-1/2) or transfected with a
dominant-negative mutant of MEK-1. The efficiency of ERK-1/2
inhibition under these conditions can be seen in Fig. 4B. No change
in JNK phosphorylation was detected upon ERK inhibition (Fig.
S1). Control cell invasion was inhibited upon U0126 treatment in a
dose-dependent manner (Fig. 4C and 4D). Moreover, shCTRLcells
overexpressing a kinase-dead form of MEK-1 exhibited reduced
invasive properties (Fig. 4C and 4D). These results indicate that the
ERK signaling module is activated during carcinoma cell invasion.
Secondly, to rescue the activated ERK pathway in LRP-1-silenced
cells, a constitutively-active ERK-2 was overexpressed. The
activation state of ERK-1/2 was assessed by immunoblotting
(Fig. 4E). As shown in Fig. 4F and 4G, the ability of LRP-1-deficient
cells to invade was partially restored when ERK-2 was overex-
pressed. Since the tyrosine-kinase Src could potentially activate
ERK signaling downstream of LRP-1 (Fig. 3), cell invasion was
quantified in the presence of a Src kinase inhibitor. However, Src
inhibition did not affect the invasive capacities of both shCTRL and
shLRP-1 cells (Fig. 4H), thereby excluding Src kinase contribution
to LRP-1-mediated ERK activation during carcinomacell invasion.
The inhibition of JNK mediated by LRP-1 sustains
malignant cell invasion
Likewise, we examined to what extent LRP-1-mediated
inhibition of the JNK pathway could support carcinoma cell
invasion. JNK1 and MKK-7 (MAPK kinase-7) were thus co-
expressed in shCTRL cells (Fig. 5A). Invasion of shCTRL cells was
reduced by 25% when overexpressing wild-type JNK (Fig. 5B and
5C), suggesting that JNK inhibition is required to promote
invasion. Next, we used the selective JNK inhibitor SP600125 and
a dominant-negative mutant of JNK to recover JNK inhibition in
LRP-1-deficient carcinomas (Fig. 5D). We did not observe any
significant modulation of ERK phosphorylation under these
conditions (Fig. S1). Interestingly, the weak capacity of LRP-1-
silenced cells to invade was significantly increased under JNK
inhibition (Fig. 5E and 5F). These results support the concept that
the inhibition of the JNK-signaling pathway mediated by LRP-1
contributes to carcinoma cell invasion.
The LRP-1-mediated regulation of MAPK controls the
attachment of carcinoma cells
We recently reported that LRP-1 silencing severely impaired
the invasion of malignant cells consecutively to a strong alteration
of cell-matrix interaction turn-over. We therefore postulated that
LRP-1-dependent control of both ERK and JNK pathways
contributes to modulate the cell-matrix interaction to support
invasiveness. As expected, shLRP-1 cells, in which ERK activity is
reduced, displayed an accelerated rate of attachment to gelatin-
coated surfaces, compared to control clonal cells (Fig. 6A).
Moreover, overexpression of a kinase-inactive MEK-1 mutant in
shCTRL cells led to increased adhesion rate (Fig. 6B), whereas
constitutively active ERK-2 decreased the capacity of LRP-1-
deficient cells to attach (Fig. 6C). Indeed, after 60 min of
attachment, adherent cells were increased 2-fold upon ERK
pathway inhibition (Fig. 6B). At the same time of attachment, the
percentage of adhering LRP-1-silenced cells was decreased 2-fold
under ERK activation (Fig. 6B and 6C). Likewise, overexpression
of wild-type MKK-7/JNK-1 in control cells led to a 2-fold
enhanced adherence after 60 min (Fig. 7A). Furthermore, the
increased attachment rate observed in LRP-1-deficient cells was
reversed by expression of a dominant-negative form of JNK-1
(Fig. 7B). These data support the concept that LRP-1 maintains
malignant cells in an intermediate adhesive state that is favorable
for invasion through ERK activation and JNK inhibition.
The actin network of fast-invading carcinomas is rescued
in LRP-1-silenced cells following reactivation of ERK or
inhibition of hyperactivated JNK
We further investigated whether the LRP-1-dependent regula-
tion of MAPK signaling could orchestrate the coordination of
actin and adhesion dynamics during malignant cell invasion. We
therefore analyzed the cellular distribution of fibrillar actin after
modulation of ERK and JNK activities (Fig. 8). Adherent control
cells displayed a polarized morphology with filopodial cell
extensions and a mainly cortically distributed actin network
(Fig. 8A). In sharp contrast, LRP-1-silencing induced overspread
morphology with numerous stress fibers, prominent transverse
Figure 4. LRP-1 controls carcinoma cell invasion through a Src-independent activation of ERK. Matrigel Invasion assay was carried out for
shCTRL and shLRP-1 carcinoma cells in basal conditions (A), following the modulation of ERK activity in shCTRL (B–D) and shLRP-1 cells (E–G)o ri n
the presence of Src inhibitor (H). (C, D) The capacity of shCTRL cells to invade matrigel was quantified after inhibition of ERK activity by using U0126
treatment (10 or 25 mM) or expression of a kinase-dead mutant for MEK-1 (dn-MEK). (F, G) The invasive properties of shLRP-1 cells were examined
after a constitutive activation of ERK-2 (ca-ERK). The efficiency of the ERK inhibition in shCTRL (B) and ERK activation in shLRP-1 cells (E) was
controlled by using phospho-ERK, ERK and b-actin antibodies. Anti-HA was used to control the level of expression of overexpressed HA-tagged
proteins. (H) Tumor cell invasion was measured after inhibition of Src-dependent activity by using 10 mM of Src kinase inhibitor I (Src inh).
Representative images are shown for each condition (D, G). Results were obtained from three separate experiments each performed in triplicate.
Invasion was determined by counting cells in eight random microscopic fields per well. Results were expressed as means +/- SD after normalization
by comparison with vehicle, i.e., DMSO for drug treatments or lipofectamine (lipo) for transfection. NS, differences with corresponding control were
not significant. *, P,0.05.
doi:10.1371/journal.pone.0011584.g004
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11584Figure 5. JNK inhibition required for carcinoma cell invasion is mediated by LRP-1. Cell invasion assays were carried out with shCTRL (B,
C) and shLRP-1 cells (E, F) after modulation of JNK activity (A, D). (B, C) ShCTRL cells were transfected by expression vector coding for wild-type
MKK-7/JNK-1 before cell invasion was quantified. (E, F) The invasive properties of LRP-1-silenced cells were measured following the SP600125
treatment (5 or 10 mM) or transfection by a dominant-negative mutant of JNK-1 (dn-JNK). JNK activation in shCTRL (A) and JNK inhibition in shLRP-1
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Inhibition of ERK signaling in control cancer cells by U0126
treatment (Fig. 8B vs 8A) or a dominant-negative form of MEK-1
(Fig. 8D vs 8C) induced drastic morphological changes similar to
those obtained under LRP-1 silencing. The same result was
observed after expression of wild type MKK-7/JNK-1 in control
carcinoma cells (Fig. 8E vs 8C). In LRP-1-silenced cells, inhibition
of JNK signaling by SP600125 (Fig. 8G vs 8F) or overexpression of
kinase-inactive JNK-1 (Fig. 8J vs 8H) restored the mesenchymal-
like morphology of wild-type carcinoma cells. Moreover, consti-
tutively-active ERK-2 (Fig. 8I vs 8H) was sufficient to reverse the
overspread morphology caused by the silencing of LRP-1. These
results demonstrated that LRP-1 silencing induces major actin
cytoskeleton rearrangements directly linked to ERK inhibition and
JNK hyperactivation.
LRP-1-dependent activation of ERK and inhibition of JNK
is necessary for FA disassembly in fast-invading
carcinomas
Considering the impact of LRP-1 silencing on the adhesive and
morphological properties of carcinoma cells (Figs. 6, 7 and 8), we
investigated whether the LRP-1-mediated control of MAPK is
necessary for FA turn-over. Thus, the cellular distribution of focal
complexes was analyzed in shCTRL and shLRP-1 cells after
differential activation of the ERK and JNK pathways (Fig. 9A to
9J). LRP-1-silencing led to accumulation of numerous and highly-
structured focal complexes at the cell periphery (Fig. 9F vs 9A).
Interference with ERK activation in control cells with U0126 (Fig. 9B
vs 9A) or a kinase-inactive form of MEK-1 (Fig. 9D vs 9C) increased
the number and size of talin-containing focal contacts to the same
extent as observed in LRP-1-silenced cells (Fig. 9F). Accordingly,
overexpression of wild-type MKK-7/JNK-1 in LRP-1 expressing
control cells stimulated the accumulation of talin-containing periph-
eral adhesion structures (Fig. 9E vs 9C). By contrast, the number of
talin-rich structures was drastically reduced in LRP-1-silenced cells by
using a selective JNK inhibitor (Fig. 9G vs 9F) or expression of a
dominant-negative JNK-1 mutant (Fig. 9J vs 9H). Similar results were
obtained when a constitutively-active ERK-2 was expressed in LRP-1-
deficient cells (Fig. 9I vs 9H). These data demonstrated that JNK
activation or ERK inhibition in LRP-1-deficient cells could restore the
initial distribution of adhesion complexes. The percentage of cells
positive for FA was subsequently quantified, as already described [17].
As shown in Fig. 9K and 9L, the number of LRP-1-expressing cancer
cells positive for talin-rich adhesion complexes was increased by about
1.4-fold under ERK inhibition (U0126 and dn-MEK) and by 1.7-fold
under JNK activation (MKK-7/JNK-1). By contrast, the increased
number of focal contacts caused by the LRP-1 silencing was partially
reversed by ERK activation (ca-ERK) or JNK inhibition (SP600125
and dn-JNK). Consequently, LRP-1 appears as a main mediator of
adhesion disruption through regulation of the ERK and JNK
signaling pathways.
LRP-1 is linked to cytoskeleton and FA components and
controls the recruitment of active MAPK to focal
complexes
To clarify the molecular mechanism by which LRP-1 controls
the FA dynamics and cytoskeletal organization through MAPK
regulation, immunoprecipitation assays were conducted (Fig. 10).
The data presented in figure 10A revealed that a-actinin, talin and
paxillin interact with the LRP-1 b-chain in fast-invading
carcinoma cells. Interestingly, we also detected an association
between LRP-1 and active phospho-Shp-2 (SH2 domain-contain-
ing protein tyrosine phosphatase-2), PP2A (serine/threonine
protein phosphatase 2A), and PAK (p-21 activated kinase) which
are key regulators of MAPK signaling. Other molecular relays
such as Ras and MEK were also found associated to LRP-1-ICD
(Fig. S2). The composition of talin-containing complexes was then
analyzed in LRP-1-silenced cells compared to control tumor cells
(Fig. 10B). As expected, an increased amount of talin was observed
in LRP-1-deficient cells. Moreover, the quantity of paxillin in
talin-containing complexes was specifically altered under LRP-1
silencing whereas the a-actinin was not. Interestingly, the active
forms of ERK were mainly detected in talin-containing complexes
of LRP-1-expressing cells. Furthermore, we observed a strong
accumulation of phospho-JNK in these complexes under LRP-1
silencing.
Discussion
Considering the lack of molecular knowledge about LRP-1 in
the cancer field, we investigated the intracellular signaling network
connecting LRP-1 to the aggressive behavior of tumor cells. Our
results highlighted that LRP-1 maintains malignant cells in an
adhesive state favorable for invasion by controlling ERK and
JNK-dependent pathways.
We first demonstrated that LRP-1 expression in carcinoma cells
triggers the serum-mediated activation of ERK and is responsible
for the constitutive inhibition of JNK. Consistent with our results,
previous studies have reported a decreased phosphorylation of
ERK-1/2 in LRP-1-deficient non-tumor cells [15,32]. On the
other hand, Ma and collaborators reported that LRP-1 could
repress ERK activation to control cell mobility [31]. In HT1080
fibrosarcoma cells, Webb and colleagues demonstrated that LRP-1
deficiency led to increased phosphorylated ERK level that
stimulates cell migration and invasion [33]. In these studies,
activation of ERK in LRP-1-deficient cells required the expression
of uPAR, the uPA receptor, which binds vitronectin. These results
appeared to be highly vitronectin-dependent since uPAR-vitro-
nectin interaction is well-known to be sufficient to initiate
downstream changes in cell migration and signal transduction
[34]. The ability of LRP-1 to mediate the endocytic uptake of
uPAR and down-regulate the cell surface amount of uPA:uPAR
complex was frequently evoked to explain the control of ERK
activation by LRP-1 [31,33,35]. However, shRNA-mediated
knock-down of LRP-1 did not affect the cell surface level of
uPAR in our model [17]. Although ERK activation was reported
in response to ligand binding to LRP-1 [15,19,32,36], a clear
overview of the underlying mechanisms is still lacking. Interest-
ingly, Src-mediated phosphorylation of LRP-1-ICD allows the
recruitment of Shc, a scaffold for Ras-ERK activation [37]. More
recently, LRP-1 was demonstrated to control ERK activation in
neuronal cells through Src-mediated transactivation of Trk
(tyrosine kinase receptor) [36]. However, despite the existence of
a molecular interaction between Src and LRP-1, a specific Src-
inhibitor did not affect the LRP-1-mediated control of cell
cells (D) was assessed by using phospho-JNK, JNK and b-actin antibodies. Anti-HA and anti-FLAG were used to control the expression of
overexpressed tagged proteins. Representative images are shown for each condition (C, F). Results were obtained from three separate experiments
each performed in triplicate. Invasion was determined by counting cells in eight random microscopic fields per well. Results were expressed as means
+/2 SD after normalization by comparison with vehicle, i.e., DMSO for drug treatments or lipofectamine (lipo) for transfections. *, P,0.05.
doi:10.1371/journal.pone.0011584.g005
LRP1 Signaling Promotes Cancer
PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11584invasion. This suggests an interesting alternative Src-independent
activating platform for ERK. Through immunoprecipitation
assays, we detected Shp-2 and PAK association with the LRP-1
b-chain (Fig. 10A). Shp-2 was previously shown to be recruited by
LRP-1-ICD and proposed to support ERK signaling during
spreading and migration [27,38,39]. Additionally, PAK was
demonstrated to phosphorylate and activate upstream elements
of the ERK pathway [40]. The prospective control of the MKK-
7/JNK-1/2/3 pathway by LRP-1 was rarely discussed, although
recent studies reported the LRP-1-mediated control of JNK
activation in microglial or fibroblastic cells [41,42]. Cross-talk
between JNK and ERK pathways may exist depending on the cell
environment. However, a clear contribution of the ERK pathway
to JNK signaling was not detected (Fig. S1). Although LRP-1 was
recently identified as an activator of the p38 MAPK pathway in
brain microvessel endothelial cells [43] and a mediator of the Akt-
mediated survival in neurons [44], we did not observe any LRP-1-
dependent modulation of these pathways under our experimental
conditions (Fig. 1C).
To our knowledge, this is the first report for the existence of
interactions between ERK and JNK-containing complexes and
full-length LRP-1. Most of the binding partners for LRP-1 were
shown to interact with the two NPxY motifs in the cytoplasmic tail
[27,38]. Additional phosphorylation at Ser 73/76/79 and Thr 16
residues were shown to control the tyrosine phosphorylation and
probably their accessibility for scaffold molecule recruitment [45].
The stable interactions established by LRP-1-ICD with ERK and
JNK may influence the ability of MAPK to reach their
downstream targets and may have a repercussion for spatial and
temporal propagation of intracellular signaling. Interestingly,
MAPK scaffolds, associated with adhesion or growth factor
receptors, were reported to persist in active signaling complexes
at the surface of endosomal vesicles [46]. Moreover, proteolytically
released LRP-1-ICD was recently reported to directly influence
transcription through nuclear shuttling [47]. It would be
interesting to examine whether LRP-1 would be able to convey
ERK or JNK to the nuclear compartment. The presence of JNK
on LRP-1-ICD is consistent with studies performed on the Reelin
receptor ApoER2 (apolipoprotein E receptor 2)/LRP-8, a close
member of the LDL receptor family [48]. Moreover, JNK-
interacting proteins JIP-1/2 (JNK-interacting protein-1/2) binding
to LRP-1-ICD was demonstrated in yeast two-hybrid and pull-
down experiments [28]. In addition, Lutz and collaborators
showed that expression of a chimeric construct harboring only the
intracellular domain of LRP-1 was sufficient to enhance JNK
activation [49]. In this study, the JIP-mediated retention of
activated JNK on LRP-1-ICD prevented the nuclear translocation
of phospho-JNK, inhibiting the expression of Elk-1 (ets-like
protein-1) and c-jun responsive genes. This retention mechanism
of active kinases probably did not occur in our carcinoma model
since we did not observe phosphorylated forms of JNK bound to
LRP-1 (Fig. 3). This could be explained by the ambivalent action
of JIP towards JNK. Depending on its ability to recruit various
Figure 6. LRP-1-silencing accelerates adhesion of carcinoma
cells to matrix substrates through ERK inhibition. (A) shCTRL
(white boxes) and shLRP-1 (grey boxes) cells were seeded onto gelatin-
coated plates and the non adherent cells were discarded after 30, 60 or
90 min. Adhesion assays were also performed with shCTRL cells
overexpressing a kinase-dead mutant for MEK-1 (dn-MEK) (B) and
shLRP-1 overexpressing a constitutively-active ERK-2 (ca-ERK) (C). For
each condition, results are expressed as percentages of corresponding
control adherent cells at 90 minutes. Each value is the mean +/2 SD for
four separate experiments, with each performed in triplicate. *, P,0.05.
doi:10.1371/journal.pone.0011584.g006
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bility to Ser/Thr- and/or Tyr-phosphatase activities associated to
the C-terminus of LRP-1 [27,38,51]. In agreement, immunopre-
cipitation assays revealed various protein phosphatases associated
with the LRP-1-ICD (Fig. 10A).
Our data demonstrated that LRP-1-mediated regulation of
MAPK signaling triggers FA dynamics of cancer cells, supporting
cell invasion. LRP-1 emerges as a main regulator of focal complex
composition by targeting paxillin, a major scaffold component
[52], and phospho-ERK to focal complexes and preventing the
localization of JNK in talin-rich structures. Active ERK and JNK
were previously identified as FA components in migratory cells
[53,54,55]. Such a localization was associated with increased
phosphorylation of structural and scaffold proteins such as paxillin,
triggering the destabilization of FA. Consistent with our results, a
recent study reported that uncontrolled JNK-mediated phosphor-
ylation of paxillin results in hypermatured adhesion complexes and
impaired migration [56]. Stress fibers, membrane protrusions and
projections of fast-invading tumor cells also appeared to be highly
regulated by the LRP-1-mediated regulation of ERK/JNK
activation. The ability of LRP-1 to target paxillin to FA could
control the spatial confinement and activation of Rho family
GTPases, well-known to regulate many aspects of actin dynamics
[52,57]. Interestingly, paxillin localization to FA was described as
a compelling element of cell polarization through spatial control of
Rac activity, a potent regulator of actin branching [58]. In
agreement, control of Rac activity by LRP-1 was previously
reported in other cell types [31,49]. Moreover, JNK are
downstream effectors of Rac and can induce the activation of
WASP (Wiskott-Aldrich syndrome protein) family proteins [59],
mediating actin nucleation in membrane ruffles. LRP-1 is likely to
support the contractile phenotype of fibroblasts by activating an
ERK/Rho/MLCK (myosin light chain kinase) pathway [32] or to
stimulate FA disassembly through RhoA inactivation [60]. The
presence of LRP-1 at the leading edge [61] could therefore
orchestrate polarization and support directional migration of
tumor cells. By sensing chemotaxis and haptotaxis gradients, the
receptor engages MAPK signaling pathways to control FA
composition and cytoskeleton organization and acts as a primary
regulator of adhesion disruption. Accordingly, LRP-1 was clearly
associated with several aspects of integrin function including their
clustering [62], signaling [25] and internalization [10,63]. Integrin
recycling is becoming established as a crucial molecular mecha-
nism that subtly controls cell migration, especially in pathological
contexts [64]. The fact that the LRP-1-ICD interacts with various
adhesion complex and cytoskeletal components reinforces the
close relation it may establish with adhesion receptors and
supports its de-adhesive properties towards matrix-engaged
integrin complexes. Accordingly, LRP-1- ICD NPxY motifs are
shared by integrin-b tails and LRP-1 was shown to bind a talin
homologue and the integrin cytoplasmic associated protein ICAP-
1 [28,64].
Finally, by regulating recruitment, activation and targeting of
some MAPK to adhesion complexes, LRP-1 contributes to
maintain an adhesive state that is favorable for invasion. Recent
results reported that LRP-1 may support metastasis development
in response to hypoxia [21] or mediate anoikis resistance [23]. As
such, LRP-1 may represent a crucial actor in the epithelial-to-
mesenchymal transition. Future investigation should focus on
identifying MAPK-modulating sequences in LRP-1-ICD to open
therapeutic perspectives in the prevention of cancer dissemination.
Materials and Methods
Antibodies and chemicals
Anti-LRP-1 a-chain (8G1), anti-LRP-1 b-chain (5A6), anti-
human IgGs used as negative control for immunoprecipitation
experiments (HP6030), specific SAPK/JNK inhibitor SP600125
(420119) and Src kinase inhibitor I (567805) were obtained from
Calbiochem (distributed by VWR International, Strasbourg,
France). Anti-ERK-1/2 (9102), anti-SAPK/JNK (9252), anti-Akt
Figure 7. LRP-1-silencing increases adhesion rate of carcinoma
cells through JNK hyperactivation. shCTRL (white boxes) and
shLRP-1 (grey boxes) cells were seeded onto gelatin-coated plates and
the non adherent cells were discarded after 30, 60 or 90 min. Adhesion
assays were performed with shCTRL cells overexpressing wild type
MKK-7/JNK1 (A) and shLRP-1 overexpressing a dominant negative
mutant of JNK-1 (dn-JNK) (B) kinases. For each condition, results are
expressed as percentages of corresponding control adherent cells at 90
minutes. Each value is the mean +/2 SD for four separate experiments,
with each performed in triplicate. *, P,0.05.
doi:10.1371/journal.pone.0011584.g007
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(9101), anti-phospho-SAPK/JNK (9251), anti-phospho-Akt
(9271), anti-phospho-p38 (9211), HRP-conjugated anti-rabbit
(7074) and specific MEK-1/2 inhibitor U0126 (9903) were from
Cell Signaling Technology (distributed by Ozyme, Saint Quentin
Yvelines, France). Anti-PP2A (1504-1), anti-phospho-Shp-2 (2165-
1) and anti-PAK (2247-1) antibodies were purchased from
Epitomics (distributed by Euromedex, Mundolsheim, France).
HRP-conjugated anti-mouse antibody (NA931V) was from
Amersham Biosciences (Buckinghamshire, UK). Anti-talin
(MAB1676) was from Chemicon (distributed by Millipore,
Molsheim, France). Anti-paxillin (clone 349) antibody was from
BD Biosciences (Le Pont de Claix, France). Anti-b-actin (sc-1616)
and anti-FLAG (sc-807) antibodies were purchased from Santa-
Cruz Biotechnology (distributed by Tebu-Bio, Le Perray en
Yvelines, France). Anti-mouse AlexaFluor 488 (A11001), Alexa-
Fluor 568-phalloidin (A12380) and Prolong Gold antifade reagent
with DAPI (P36935) were from Molecular Probes (Cergy Pontoise,
France). Anti-HA antibody (clone 12CA5) was purchased from
Roche Diagnostics (Meylan, France). Anti-a-actinin (BM-75.2),
HRP-conjugated anti-goat secondary antibodies (A5420) and
other chemicals were from Sigma-Aldrich (Saint Quentin
Fallavier, France).
Plasmids
LRP-1 knockdown was achieved by RNA interference using a
previously validated vector-based shRNA approach [17]. Con-
stitutively-active HA-tagged ERK-2 (ca-ERK) and the HA-
tagged kinase-dead mutants of MEK-1 (dn-MEK) and JNK-1
(dn-JNK) were generated as described elsewhere [65]. Wild-type
MKK-7/JNK-1 vector (FLAG-tagged) was generous gift from
Dr. Roger Davis (HHMI, University of Massachusetts Medical
School).
Cell culture and transfection
The human FTC133 cell line was obtained from a lymph node
metastasis of a follicular thyroid carcinoma [66]. This cell line was
supplied by the European Collection of Cell Cultures, ECACC.
Cells were grown in Dulbecco’s Modified Eagle Medium-Ham’s
F12 (Invitrogen, Cergy Pontoise, France) with 10% fetal bovine
serum (FBS), as previously described [67]. Generation of two
clonal cell lines that stably overexpress a non-silencing sequence
(shCTRL) or a specific short hairpin RNA (shRNA) for LRP-1
(shLRP-1) was described elsewhere [17]. For transient transfection
assays, plasmids were transfected for four hours by using
Lipofectamine 2000 (Invitrogen) according to the manufacturer
instructions.
RNA isolation and RT-PCR
Total RNAs were isolated and purified with an RNeasy
isolation kit (Qiagen, Courtaboeuf, France) and RT-PCR (reverse
transcription and polymerase chain reaction) was performed as
recommended by the manufacturer (Promega, Charbonnie `res,
France). Previously described primers for human LRP-1 [17] and
primers for b-actin: forward, GTGTGACGTGGACATCCGC;
reverse, CTGCATCCTGTCGGCAATG; were synthesized by
Eurogentec (Angers, France). Numbers of cycles were adjusted to
ensure that amplifications were in a linear range. The gels shown
are representative of at least three separate experiments.
Figure 8. LRP-1 controls carcinoma cells spreading and cytoskeleton organization through MAPK regulation. shCTRL (A–E) and shLRP-
1( F–J) cells were seeded onto gelatin-coated plates for 120 min. ERK or JNK activities were modulated. Control cells were treated by 25 mM U0126
(B) or transfected by a kinase-dead mutant for MEK-1 (dn-MEK) (D) to inhibit the ERK-dependent pathway and JNK activation was obtained by
overexpression of both wild-type MKK-7 and JNK-1 (E). For LRP-1-deficient cells, inhibition of JNK pathway was achieved by using SP600125
treatment (10 mM) (G) or overexpression of a dominant-negative form of JNK-1 (J), while the reactivation of ERK pathway was obtained by using an
expression vector for constitutively-active ERK-2 (I). DMSO (A, F) served as control for drug treatments (B, G) and lipofectamine (C, H) served as
control for transfection assays (D, E, I, J). Cells were stained for actin filaments (red) and nuclei were counterstained with DAPI (blue). Images are
representative of at least three separate sets of cultures. Bars, 20 mm.
doi:10.1371/journal.pone.0011584.g008
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Whole-cell extracts were prepared by scraping cells in ice-cold
lysis buffer (25 mM Tris-HCl, pH 7.7, 150 mM NaCl, 0.5%
glycerol, 1% Triton X-114, 5 mM EDTA, 0.5 mM EGTA,
1 mM phenylmethylsulfonyl fluoride, 1 mM orthovanadate
supplemented with proteinase inhibitor cocktail from Sigma-
Aldrich). After 30 min incubation on ice, extracts were
centrifugated (10,0006 g for 10 min at 4uC) and pellets were
discarded. The protein concentration in supernatants was
quantified by the Bradford method (Bio-Rad Laboratories,
Marnes-la-Coquette, France). Proteins were separated by elec-
trophoresis in a 10% sodium dodecyl sulfate-polyacrylamide gel,
transferred onto a nitrocellulose membrane (Whatman GmbH,
Dassel, Germany), and incubated overnight at 4uCw i t hp r i m a r y
antibodies. Immunoreactive bands were revealed with an ECL
plus chemiluminescence kit from Amersham Biosciences by using
a ChemiDoc-XRS imaging station from Bio-Rad. Immunoblots
presented are representative of at least three separate exper-
Figure 9. LRP-1 silencing prevents disassembly of focal adhesions through inhibition of ERK and hyperactivation of JNK. (A–J)
shCTRL (A–E) and shLRP-1 (F–J) cells were seeded onto gelatin-coated plates for 120 min. ERK signaling pathway was inhibited in shCTRL cells by
using 25 mM U0126 (B) or a kinase-dead MEK-1 mutant (dn-MEK) (D) and reactivated in shLRP-1 cells by a constitutive activation of ERK-2 (ca-ERK) (I).
The MKK-7/JNK1 vector was used to trigger JNK activation in shCTRL cells (E) while JNK inhibition in LRP-1-deficient cells was obtained by using a
10 mM SP600125 (G) or a dead-kinase for JNK-1 (dn-JNK) (J). DMSO (A, F) served as a control for drug treatments (B, G) and lipofectamine (C, H)
served as a control for transfections (D, E, I, J). Cells were then stained for talin (green) and nuclei were counterstained with DAPI (blue). Images are
representative of at least three separate sets of cultures. Bars, 20 mm. (K, L). The percent of cells positive for focal adhesions was quantified following
the modulation of ERK and JNK activities by using selective drug treatments (K) or the indicated MAPK construct (L). For each condition, three
hundred cells from three separate experiments were evaluated. Results were expressed in percent, compared to shCTRL cells treated by DMSO (K)o r
lipofectamine (L). *, P,0.05.
doi:10.1371/journal.pone.0011584.g009
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cells were plated on gelatin-coated surfaces and whole-cell extracts were used to perform immunoprecipitation experiments (IP). (A)
Immunoprecipitation of LRP-1-containing complexes was performed by using the monoclonal anti-LRP-1 antibodies (8G1). Immunocomplexes
were then immunoblotted (IB) by using specific antibodies for LRP-1 b-chain, a-actinin, talin, paxillin, phospho-Shp-2, PP2A and PAK. (B) Talin-
containing complexes were immunoprecipitated and analyzed by Western-blot by using anti-talin, anti-phospho-ERK, anti-phospho-JNK, anti-a-
actinin and anti-paxillin antibodies. Nonspecific IgGs were used as a negative control of immunoprecipitation assays.
doi:10.1371/journal.pone.0011584.g010
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loading.
Immunoprecipitation
The procedure is adapted from [17]. Briefly, for the
immunoprecipitation of LRP-1 containing complexes, cell extracts
were prepared in the following lysis buffer: 10 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100,
1 mM phenylmethylsulfonyl fluoride, 1 mM orthovanadate sup-
plemented with proteinase inhibitor cocktail from Sigma-Aldrich.
Cell extracts for immunoprecipitation of talin-containing com-
plexes were prepared in a distinct lysis buffer (10 mM Tris-HCl,
pH 6.7, 0.75% Brij, 75 mM NaCl, 5 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, 1 mM orthovanadate supplement-
ed with proteinase inhibitor cocktail). After centrifugation
(10,0006 g, 10 min at 4uC) and Bradford titration, 500 mgo f
proteins were incubated for 4 hours at 4uC on an orbital agitator
in presence of anti-LRP-1, anti-talin or nonspecific IgGs.
Immunoprecipitation was performed with 40 mL protein G-
Sepharose (Amersham Biosciences) for 2 hours at 4uC with
constant shaking. The samples were washed three times in the
corresponding lysis buffer and protein complexes bound to beads
were solubilized under reducing conditions and analyzed by
immunoblotting as described above.
Boyden chamber assay
Matrigel invasion assay was performed using modified Boyden
chambers in 24-well dishes with Transwell filter inserts provided
with 8-mm pores (Costar, Fisher Scientific Labosi, Elancourt,
France), as described elsewhere [67]. Invasiveness was determined
by counting cells in eight random microscopic fields per well each
seeded in triplicate.
Adhesion assay
Cancer cell adhesion to gelatin-coated surfaces was measured as
previously described [17]. All conditions were assessed in
quadruplicate and each presented experiment was performed at
least three times.
Immunofluorescence microscopy
Clonal FTC133 cells were seeded onto gelatin-coated coverslips
for 2 hours at 37uC, fixed with 4% paraformaldehyde for 5 min
on ice and then permeabilized in ice-cold 0,1% Triton X-100 for
10 min. After three washes with PBS (Phosphate Buffered Saline),
cells were incubated 30 min with PBS containing 2% bovine
serum albumin to saturate non specific antigens. Coverslips were
then incubated for 30 min with AlexaFluor 568-phalloidin or
60 min with anti-talin antibodies followed by three washes with
PBS. Talin staining was revealed after 30 min incubation with
secondary antibodies conjugated to AlexaFluor 488. Coverslips
were then mounted in Prolong Gold antifade medium with 49,6-
diamino-2-phenylindole (DAPI) to obtain nuclei counterstaining.
Acquisition was performed with an Olympus BH2-RFCA
epifluorescence microscope (Olympus, Japan), equipped with a
100W mercury lamp (OSRAM, GmbH), using a SPlan achromat
x 40 objective (Olympus) and fluorescein, rhodamin, DAPI filters
for talin, actin and nuclei staining, respectively. Representative
images from three separate sets of cultures were treated and
merged with ImageJ sofware. The percentage of cells positive for
FA was determined as previously reported [17], by examining 300
cells from three different experiments for each condition.
Densitometric analysis and statistical evaluation
Bands from immunoblots or agarose gels were quantified by
using Quantity One image-analyser software (Bio-Rad Laborato-
ries). All culture assays were normalized on the basis of cell
viability by using the CellTiter-Glo assay from Promega. Each
experiment was performed at least in triplicate and data were
expressed as mean +/2 SD. Comparisons were performed using
Student’s t-test (Prism software, GraphPad Inc). Differences from
control: NS, not significant; *, P,0.05.
Supporting Information
Figure S1 Analysis of potential cross-talk between ERK and
JNK pathways. shCTRL and shLRP-1 cells were plated on
gelatin-coated dishes for 24 hours in the presence of FBS. Whole-
cell extracts were subjected to immunoblot analysis to study the
activation of ERKs (A) and JNKs (B) in the absence or presence of
SP600125 (10 mM) and U0126 (25 mM), respectively. Antibodies
specific to ERK (A) and JNK (B) kinases were used to ensure equal
loading. The immunoblots presented are representative of at least
three separate experiments.
Found at: doi:10.1371/journal.pone.0011584.s001 (0.41 MB TIF)
Figure S2 Ras and MEK are co-immunoprecipitated with LRP-
1-in tumor cells. Cell lysates from shCTRL cells were subjected to
immunoprecipitation assays using anti-LRP-1 alpha-chain anti-
bodies (IP: LRP-1). The immunocomplexes were then immun-
blotted (IB) with anti-LRP-1 beta-chain (5A6), anti-Ras (2006992,
Millipore), anti-Raf (sc-166, Santa-Cruz) and anti-MEK-1/2 (sc-
436, Santa-Cruz) antibodies. Nonspecific IgGs were used as the
negative control for immunoprecipitation.
Found at: doi:10.1371/journal.pone.0011584.s002 (0.28 MB TIF)
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